Literature DB >> 11338057

Hypersplenism.

M Peck-Radosavljevic1.   

Abstract

Cytopenias in liver disease are a common finding. In the past they have mostly been attributed to pooling and/or destruction of blood cells in the enlarged spleen, leading to the term 'hypersplenism'. With recent advances in the understanding of the physiology of blood formation, in particular with the discovery of several haematopoietic growth factors, new insight into the pathophysiology of blood cell derangements in liver disease has been obtained. Recombinant haematopoietic growth factors present new opportunities for support of the haematopoietic system, which is required because of toxic antiviral therapies or surgical interventions in these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11338057     DOI: 10.1097/00042737-200104000-00004

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  24 in total

1.  Role of partial splenic arterial embolization for hypersplenism in patients with liver cirrhosis and thrombocytopenia.

Authors:  Heba M Abdella; Amal T Abd-El-Moez; Mohammed E Abu El-Maaty; Ali Z Helmy
Journal:  Indian J Gastroenterol       Date:  2010-05-05

2.  Long-term postoperative outcomes of hypersplenism: laparoscopic versus open splenectomy secondary to liver cirrhosis.

Authors:  Jin Zhou; Zhong Wu; Prasoon Pankaj; Bing Peng
Journal:  Surg Endosc       Date:  2012-05-31       Impact factor: 4.584

3.  Medical and surgical management of portal hypertension in children.

Authors:  Riccardo A Superina; Estella M Alonso
Journal:  Curr Treat Options Gastroenterol       Date:  2006-09

4.  Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly.

Authors:  Kazuaki Tejima; Ryota Masuzaki; Hitoshi Ikeda; Haruhiko Yoshida; Ryosuke Tateishi; Yosuke Sugioka; Yukio Kume; Tomoko Okano; Tomomi Iwai; Hiroaki Gotoh; Sachiko Katoh; Atsushi Suzuki; Yukako Koike; Yutaka Yatomi; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2010-03-26       Impact factor: 7.527

5.  Severe thrombocytopenia due to hypersplenism treated with partial splenic embolisation.

Authors:  Mohammad Hanafiah; Azura Mohamed Mukhari Shahizon; Soo Fin Low; Man Harun Shahrina
Journal:  BMJ Case Rep       Date:  2013-07-05

6.  Changes in count and function of splenic lymphocytes from patients with portal hypertension.

Authors:  Zong-Fang Li; Shu Zhang; Gao-Bo Lv; Ying Huang; Wei Zhang; Song Ren; Jun Yang; Shuang-Suo Dang
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

7.  Does splenectomy in cystic fibrosis related liver disease improve lung function and nutritional status? A case series.

Authors:  B Linnane; M R Oliver; P J Robinson
Journal:  Arch Dis Child       Date:  2006-05-31       Impact factor: 3.791

8.  Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.

Authors:  V Saxena; M M Manos; H S Yee; L Catalli; E Wayne; R C Murphy; V A Shvachko; M P Pauly; J Chua; A Monto; N A Terrault
Journal:  Aliment Pharmacol Ther       Date:  2014-03-24       Impact factor: 8.171

9.  Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis.

Authors:  Amir A Qamar; Norman D Grace; Roberto J Groszmann; Guadalupe Garcia-Tsao; Jaime Bosch; Andrew K Burroughs; Cristina Ripoll; Rie Maurer; Ramon Planas; Angels Escorsell; Juan Carlos Garcia-Pagan; David Patch; Daniel S Matloff; Robert Makuch; Gabriel Rendon
Journal:  Clin Gastroenterol Hepatol       Date:  2009-03-10       Impact factor: 11.382

10.  Consecutive laparoscopic gallbladder and spleen resections in cirrhotic patients.

Authors:  Ming-Jun Wang; Jun-Li Li; Jin Zhou; Zhong Wu; Bing Peng
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.